What's in Universidade do Vale do Sapucai's pipeline?

Universidade do Vale do Sapucai has 10 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 8 in Phase 1.

Which companies overlap with Universidade do Vale do Sapucai's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universidade-do-vale-do-sapucai.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Universidade do Vale do Sapucai — Portfolio Competitive Intelligence Brief

Universidade do Vale do Sapucai pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Group Hydroxychloroquine and apixaban	Group Hydroxychloroquine and apixaban	phase 3	Combination therapy: antimalarial immunomodulator + anticoagulant	Hydroxychloroquine: lysosomal pH and immune signaling; Apixaban: Factor Xa	Immunology / Rheumatology / Cardiovascular

Therapeutic area mix

Immunology / Rheumatology / Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Universidade do Vale do Sapucai:

Cite this brief

Drug Landscape (2026). Universidade do Vale do Sapucai — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidade-do-vale-do-sapucai. Accessed 2026-05-16.